## Hannah K Knudsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2460510/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EMOTIONAL EXHAUSTION AND TURNOVER INTENTION IN HUMAN SERVICE OCCUPATIONS: THE PROTECTIVE ROLE OF COWORKER SUPPORT. Sociological Spectrum, 2007, 28, 81-104.	1.9	182
2	Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers, and Intentions. Substance Abuse, 2012, 33, 9-18.	2.3	179
3	Adoption and Implementation of Medications in Addiction Treatment Programs. Journal of Addiction Medicine, 2011, 5, 21-27.	2.6	156
4	Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors, 2011, 36, 584-589.	3.0	133
5	Modeling the use of innovations in private treatment organizations: The role of absorptive capacity. Journal of Substance Abuse Treatment, 2004, 26, 51-59.	2.8	129
6	Clinical supervision, emotional exhaustion, and turnover intention: A study of substance abuse treatment counselors in the Clinical Trials Network of the National Institute on Drug Abuse. Journal of Substance Abuse Treatment, 2008, 35, 387-395.	2.8	126
7	Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment, 2006, 30, 363-373.	2.8	120
8	Retaining counseling staff at substance abuse treatment centers: effects of management practices. Journal of Substance Abuse Treatment, 2003, 24, 129-135.	2.8	114
9	Counselor emotional exhaustion and turnover intention in therapeutic communities. Journal of Substance Abuse Treatment, 2006, 31, 173-180.	2.8	114
10	Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment, 2005, 29, 95-106.	2.8	112
11	Turnover intention and emotional exhaustion "at the top": Adapting the job demands-resources model to leaders of addiction treatment organizations Journal of Occupational Health Psychology, 2009, 14, 84-95.	3.3	111
12	Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Evaluation and Program Planning, 2011, 34, 375-381.	1.6	107
13	Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment, 2007, 32, 321-329.	2.8	103
14	The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence, 2007, 87, 164-174.	3.2	85
15	Patterns of organization and management in private and public substance abuse treatment programs. Journal of Substance Abuse Treatment, 2006, 31, 235-243.	2.8	74
16	Trends in the Adoption of Medications for Alcohol Dependence. Journal of Clinical Psychopharmacology, 2006, 26, S13-S19.	1.4	73
17	The Use of Antidepressant Medications in Substance Abuse Treatment: The Public-Private Distinction, Organizational Compatibility, and the Environment. Journal of Health and Social Behavior, 2007, 48, 195-210.	4.8	73
18	Service Delivery in Substance Abuse Treatment: Reexamining "Comprehensive―Care. Journal of Behavioral Health Services and Research, 2007, 34, 121-136.	1.4	69

HANNAH K KNUDSEN

#	Article	IF	CITATIONS
19	Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. American Journal of Drug and Alcohol Abuse, 2017, 43, 215-225.	2.1	68
20	Structural and Cultural Barriers to the Adoption of Smoking Cessation Services in Addiction Treatment Organizations. Journal of Addictive Diseases, 2010, 29, 294-305.	1.3	67
21	The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. Journal of Studies on Alcohol and Drugs, 2015, 76, 644-654.	1.0	65
22	Juvenile Justice—Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS): a cluster randomized trial targeting system-wide improvement in substance use services. Implementation Science, 2015, 11, 57.	6.9	62
23	A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2010, 38, S44-S52.	2.8	56
24	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug and Alcohol Dependence, 2020, 217, 108335.	3.2	50
25	Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2009, 37, 307-312.	2.8	49
26	Research participation and turnover intention: An exploratory analysis of substance abuse counselors. Journal of Substance Abuse Treatment, 2007, 33, 211-217.	2.8	48
27	Research Network Involvement and Addiction Treatment Center Staff: Counselor Attitudes toward Buprenorphine. American Journal on Addictions, 2007, 16, 365-371.	1.4	47
28	Disparities in Access to Physicians and Medications for the Treatment of Substance Use Disorders Between Publicly and Privately Funded Treatment Programs in the United States. Journal of Studies on Alcohol and Drugs, 2013, 74, 258-265.	1.0	47
29	Adolescent-only substance abuse treatment: Availability and adoption of components of quality. Journal of Substance Abuse Treatment, 2009, 36, 195-204.	2.8	46
30	Facilitating Factors and Barriers to the Use of Medications in Publicly Funded Addiction Treatment Organizations. Journal of Addiction Medicine, 2010, 4, 99-107.	2.6	46
31	Counselor Turnover in Substance Abuse Treatment Centers: An Organizational-Level Analysis. Sociological Inquiry, 2007, 77, 166-193.	2.0	45
32	The implementation of tobacco-related brief interventions in substance abuse treatment: A national study of counselors. Journal of Substance Abuse Treatment, 2010, 38, 212-219.	2.8	45
33	Counselor Attitudes toward the Use of Motivational Incentives in Addiction Treatment. American Journal on Addictions, 2010, 19, 496-503.	1.4	42
34	Partner Relationships and HIV Risk Behaviors Among Women Offenders. Journal of Psychoactive Drugs, 2008, 40, 471-481.	1.7	37
35	The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation. Journal of Substance Abuse Treatment, 2010, 38, 275-283.	2.8	36
36	The Implementation of Smoking Cessation Counseling in Substance Abuse Treatment. Journal of Behavioral Health Services and Research, 2012, 39, 28-41.	1.4	35

Hannah K Knudsen

#	Article	IF	CITATIONS
37	Quality of clinical supervision and counselor emotional exhaustion: The potential mediating roles of organizational and occupational commitment. Journal of Substance Abuse Treatment, 2013, 44, 528-533.	2.8	35
38	Modified Therapeutic Communities and Adherence to Traditional Elements. Journal of Psychoactive Drugs, 2009, 41, 275-283.	1.7	34
39	Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. Drug and Alcohol Dependence, 2017, 173, S55-S64.	3.2	34
40	Organizational Predictors of Pharmacological Innovation Adoption: The Case of Disulfiram. Journal of Drug Issues, 2005, 35, 559-573.	1.2	32
41	Sustainment of Smoking Cessation Programs in Substance Use Disorder Treatment Organizations. Nicotine and Tobacco Research, 2013, 15, 1060-1068.	2.6	31
42	Reducing risky relationships: a multisite randomized trial of a prison-based intervention for reducing HIV sexual risk behaviors among women with a history of drug use. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1071-1079.	1.2	31
43	States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug and Alcohol Dependence, 2015, 157, 36-43.	3.2	31
44	Effects of an Organizational Linkage Intervention on Inter-Organizational Service Coordination Between Probation/Parole Agencies and Community Treatment Providers. Administration and Policy in Mental Health and Mental Health Services Research, 2016, 43, 105-121.	2.1	30
45	A Longitudinal Examination of Alcohol Pharmacotherapy Adoption in Substance Use Disorder Treatment Programs: Patterns of Sustainability and Discontinuation. Journal of Studies on Alcohol and Drugs, 2011, 72, 669-677.	1.0	29
46	Risky Relationships: Targeting HIV Prevention for Women Offenders. AIDS Education and Prevention, 2012, 24, 339-349.	1.1	29
47	Financial Factors and the Implementation of Medications for Treating Opioid Use Disorders. Journal of Addiction Medicine, 2012, 6, 280-286.	2.6	28
48	Availability of nicotine replacement therapy in substance use disorder treatment: Longitudinal patterns of adoption, sustainability, and discontinuation. Drug and Alcohol Dependence, 2011, 118, 244-250.	3.2	27
49	Perceptions of the State Policy Environment and Adoption of Medications in the Treatment of Substance Use Disorders. Psychiatric Services, 2012, 63, 19-25.	2.0	25
50	Drug Abuse Treatment Beyond Prison Walls. Addiction Science & amp; Clinical Practice, 2009, 5, 24-30.	2.6	25
51	Racial and Ethnic Disparities in SSRI Availability in Substance Abuse Treatment. Psychiatric Services, 2007, 58, 55-62.	2.0	24
52	Model and approach for assessing implementation context and fidelity in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108330.	3.2	22
53	Does service diversification enhance organizational survival?. Journal of Behavioral Health Services and Research, 2005, 32, 241-252.	1.4	18
54	Innovation Attributes and Adoption Decisions: Perspectives from Leaders of a National Sample of Addiction Treatment Organizations. Journal of Substance Abuse Treatment, 2015, 49, 1-7.	2.8	18

HANNAH K KNUDSEN

#	Article	IF	CITATIONS
55	Examination of an interventionist-led HIV intervention among criminal justice-involved female prisoners. Journal of Experimental Criminology, 2009, 5, 245-272.	2.9	17
56	Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations. Sociological Focus, 2009, 42, 133-151.	0.4	17
57	Dissemination, Adoption, and Implementation of Acamprosate for Treating Alcohol Use Disorders. Journal of Studies on Alcohol and Drugs, 2014, 75, 467-475.	1.0	17
58	Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment. Journal of Behavioral Health Services and Research, 2019, 46, 151-163.	1.4	17
59	Substance Abuse Treatment Counselors and Tobacco Use: A Comparison of Comprehensive and Indoor-Only Workplace Smoking Bans. Nicotine and Tobacco Research, 2010, 12, 1151-1155.	2.6	16
60	Adoption of the 275-Patient Buprenorphine Treatment Waiver for Treating Opioid Use Disorder: A State-Level Longitudinal Analysis. Substance Abuse, 2020, 41, 259-268.	2.3	16
61	Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers. Journal of Addiction Medicine, 2018, 12, 31-39.	2.6	16
62	Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use. Journal of Behavioral Health Services and Research, 2020, 47, 439-448.	1.4	15
63	Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties. Addictive Behaviors, 2019, 93, 72-77.	3.0	14
64	Timing of buprenorphine adoption by privately funded substance abuse treatment programs: The role of institutional and resource-based interorganizational linkages. Journal of Substance Abuse Treatment, 2012, 42, 16-24.	2.8	12
65	The Transition to Medication Adoption in Publicly Funded Substance Use Disorder Treatment Programs: Organizational Structure, Culture, and Resources. Journal of Studies on Alcohol and Drugs, 2014, 75, 476-485.	1.0	12
66	Substance use prevention services in juvenile justice and behavioral health: results from a national survey. Health and Justice, 2020, 8, 11.	2.1	12
67	The Prevalence and Negative Impacts of Substance Use Disorders among People with HIV in the United States: A Real-Time Delphi Survey of Key Stakeholders. AIDS and Behavior, 2021, , 1.	2.7	12
68	Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention. Journal of Substance Abuse Treatment, 2022, 138, 108731.	2.8	12
69	Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2011, 40, 307-312.	2.8	11
70	Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implementation Science, 2017, 12, 135.	6.9	11
71	Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. Journal of Substance Abuse Treatment, 2013, 44, 120-125.	2.8	10
72	Physicians in the substance abuse treatment workforce: Understanding their employment within publicly funded treatment organizations. Journal of Substance Abuse Treatment, 2012, 43, 152-160.	2.8	9

Hannah K Knudsen

#	Article	IF	CITATIONS
73	Implementation of Network for the Improvement of Addiction Treatment (NIATx) Processes in Substance Use Disorder Treatment Centers. Journal of Behavioral Health Services and Research, 2016, 43, 354-365.	1.4	9
74	Physicians' satisfaction with providing buprenorphine treatment. Addiction Science & Clinical Practice, 2019, 14, 34.	2.6	9
75	Medicaid, Private Insurance, and the Availability of Smoking Cessation Interventions in Substance Use Disorder Treatment. Psychiatric Services, 2015, 66, 1213-1220.	2.0	8
76	Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs. Journal of Addiction Medicine, 2019, 13, 28-34.	2.6	8
77	Recent Increase in Methamphetamine Use in a Cohort of Rural People Who Use Drugs: Further Evidence for the Emergence of Twin Epidemics. Frontiers in Psychiatry, 2021, 12, 805002.	2.6	8
78	Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations. Substance Abuse, 2016, 37, 230-237.	2.3	7
79	Smoking Cessation Services in Adolescent Substance Abuse Treatment: Opportunities Missed?. Journal of Drug Issues, 2009, 39, 257-276.	1.2	6
80	US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress. Drug and Alcohol Dependence, 2019, 204, 107490.	3.2	6
81	The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States. Drug and Alcohol Dependence, 2022, 232, 109336.	3.2	6
82	The relationship between Clinical Trial Network protocol involvement and quality of substance use disorder treatment. Journal of Substance Abuse Treatment, 2014, 46, 232-237.	2.8	5
83	Longitudinal trends in nonmedical prescription opioid use in a cohort of rural Appalachian people who use drugs. Preventive Medicine, 2020, 140, 106194.	3.4	5
84	Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysis. International Journal of Drug Policy, 2019, 70, 8-14.	3.3	4
85	Resilience-Focused HIV Care to Promote Psychological Well-Being During COVID-19 and Other Catastrophes. Frontiers in Public Health, 2021, 9, 705573.	2.7	4
86	Using conjoint analysis to study health policy changes: An example from a cohort of persons who use drugs. International Journal of Drug Policy, 2021, 98, 103425.	3.3	4
87	Addiction Nursing and the Quality of Adolescent Substance Abuse Treatment. Journal of Addictions Nursing, 2009, 20, 169-171.	0.4	3
88	The Employment of Nurses in Publicly Funded Substance Abuse Treatment Programs. Journal of Addictions Nursing, 2012, 23, 174-180.	0.4	3
89	Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers. Journal of Psychoactive Drugs, 2017, 49, 111-121.	1.7	3
90	The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. Journal of Substance Abuse Treatment, 2016, 62, 62-67.	2.8	2

HANNAH K KNUDSEN

#	Article	IF	CITATIONS
91	Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD. Health and Justice, 2021, 9, 4.	2.1	2
92	The Setting-Intervention Fit of Nine Evidence-Based Interventions for Substance Use Disorders Within HIV Service Organizations Across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, S206-S214.	2.1	2
93	Author's response: smoking cessation treatment in substance use disorder settings. American Journal of Drug and Alcohol Abuse, 2017, 43, 624-624.	2.1	О
94	Prescribers' satisfaction with delivering medications for opioid use disorder. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 78.	2.2	0